Editorial: serologic antibodies in primary sclerosing cholangitis—a tell‐tale sign of compromised gut‐liver immunity? Authors' reply-Reference-Cited by-同舟云学术

Editorial: serologic antibodies in primary sclerosing cholangitis—a tell‐tale sign of compromised gut‐liver immunity? Authors' reply

Published:2020-12-25 Issue:2 Volume:53 Page:352-353
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Wunsch Ewa¹^ORCID,Milkiewicz Piotr¹²³^ORCID

Affiliation:

1. Translational Medicine Group Pomeranian Medical University in Szczecin Szczecin Poland

2. Liver and Internal Medicine Unit Medical University of Warsaw Warsaw Poland

3. European Reference Network for Rare Liver Diseases Warsaw Poland

Abstract

LINKED CONTENT This article is linked to Wunschi et al and Tornai & Papp papers. To view these articles, visit https://doi.org/10.1111/apt.16153 and https://doi.org/10.1111/apt.16201

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16221

Reference8 articles.

1. Editorial: serologic antibodies in primary sclerosing cholangitis – a tell‐tale sign of compromised gut‐liver immunity?

2. Anti‐glycoprotein 2 (anti‐GP2) IgA and anti‐neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3‐ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis

3. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia

4. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis

5. PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC)